← Issue №20/ week of Nov 15, 2026/ the whole section, in full

Endoscopy, in full.

All 10 Endoscopy papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 10, in full

most clinically useful first · the 1 the issue led with is ruled in green
Endoscopy rct · n=551 · Nov 12, 2026 · GIE · IF 8.0

Effect of Dose Interval on Split-dose Bowel Preparation: A Multicenter Noninferiority Randomized Controlled Trial.

New evidencecolonoscopyendoscopy qualitycolorectal cancer screening
Clinical takeawayConsider offering patients flexibility in OSS split-dose timing (6-8 hours or 10-12 hours) based on convenience, as both intervals achieve similar bowel preparation quality and safety.
What it foundShort-interval (6-8 hours) and long-interval (10-12 hours) OSS split-dose regimens had comparable adequate bowel preparation rates (96.0% vs. 96.7%, difference -0.7%, 95% CI -3.8% to 2.4%).
ContextConfirms that shorter intervals for split-dose OSS are non-inferior to longer intervals, refining current practice by supporting flexible timing without compromising efficacy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Sui X … Bai Y · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy prospective cohort · n=134 · Nov 12, 2026 · Am J Gastro · IF 9.8

A Prospective Tandem Colonoscopy Study to Determine Proximal Colon Polyp Miss Rate Among Gastroenterology Trainees.

New evidencecolonoscopypolypectomyendoscopy qualityadenoma
Clinical takeawayConsider tandem colonoscopy assessments during training to objectively measure trainee polyp miss rates, particularly for sessile serrated polyps in the proximal colon.
What it foundTrainees missed 42.6% of proximal colon neoplastic polyps, including 38.1% of tubular adenomas and 58.9% of sessile serrated polyps.
ContextChallenges the reliance on adenoma detection rate (ADR) alone as a metric for trainee competence, highlighting the need for more objective measures of colonoscopy quality.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Siegel A … Keswani RN · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Endoscopy meta analysis · n=2,060 · Nov 13, 2026 · J Gastro Hep · IF 3.5

Aggressive Versus Standard Periprocedural Hydration With Lactated Ringer's Solution for the Prevention of Post-ERCP Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

New evidenceERCPmeta-analysissystematic reviewpancreatic cancer
Clinical takeawayWhen rectal NSAIDs are not used, aggressive periprocedural lactated Ringer's may reduce post-ERCP pancreatitis (low certainty); added benefit with rectal NSAIDs is unproven, and fluid overload was too infrequent to assess (6 events).
What it foundIn nine RCTs (2060 patients) of first-time ERCP, aggressive versus standard lactated Ringer's reduced post-ERCP pancreatitis from 13.6% to 5.2% (RR 0.39; 95% CI 0.27-0.56; low certainty); in the three low-risk-of-bias trials, RR 0.52 (95% CI 0.26-1.03).
ContextRefines prior evidence by isolating the effect of hydration volume from fluid composition, supporting aggressive hydration in patients not on rectal NSAIDs.
Emergingsuggested applicable standard· American Society for Gastrointestinal Endoscopy (ASGE), 'American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: summary and recommendations' (Buxbaum JL et al., Gastrointest Endosc 2023;97(2):153-162). DOI 10.1016/j.gie.2022.10.005, PMID 36517310.

… Aggressive periprocedural/postprocedural IV hydration with lactated Ringer's (20 mL/kg bolus, then 3 mL/kg/h for 8h) is a conditional suggestion for unselected patients (most practical for inpatients), and wire-guided cannulation is conditionally favored over contrast-guided to reduce PEP risk. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For ALL patients undergoing ERCP (average-risk and high-risk alike), give periprocedural rectal NSAID prophylaxis (100 mg indomethacin or diclofenac) unless contraindicated (e.g., recent PUD, renal insufficiency), this is now a strong recommendation for unselected patients, not just high-risk ones. For high-risk patients undergoing repeated or deep pancreatic-duct access or ampullectomy, add a prophylactic small-caliber pancreatic duct stent (3-5Fr, preferably 5Fr, 3-7cm, removed within 5-10 days), strong recommendation; for other high-risk scenarios (difficult cannulation, prior PEP, precut sphincterotomy without fistulotomy), PD stenting is a conditional recommendation when PD access is easily achieved. Aggressive periprocedural/postprocedural IV hydration with lactated Ringer's (20 mL/kg bolus, then 3 mL/kg/h for 8h) is a conditional suggestion for unselected patients (most practical for inpatients), and wire-guided cannulation is conditionally favored over contrast-guided to reduce PEP risk. The SVI trial (Elmunzer, Lancet 2024) found rectal indomethacin alone did NOT meet non-inferiority versus indomethacin+stent in high-risk patients (PEP 14.9% vs 11.3%), supporting continued use of the combination bundle in high-risk cases rather than dropping the stent. Post-procedure, monitor for the major complications (pancreatitis, sphincterotomy bleeding, perforation, cholangitis) and manage by type, PEP by Cotton criteria with fluids/analgesia, bleeding with repeat endoscopic hemostasis, perforation by Stapfer classification with surgical consult for Type I, and cholangitis with empiric antibiotics (Tokyo Guidelines TG18) plus biliary drainage; these complication-management elements are unchanged from ESGE 2020.

American Society for Gastrointestinal Endoscopy (ASGE), 'American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: summary and recommendations' (Buxbaum JL et al., Gastrointest Endosc 2023;97(2):153-162). DOI 10.1016/j.gie.2022.10.005, PMID 36517310. · reviewed 2026-07-21 ↗
Al-Harbi FA … Abdallfatah A · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
Endoscopy retrospective · n=250 · Nov 10, 2026 · Clin Gastro Hep · IF 16.2

A pragmatic endoscopic/histological classification of immune checkpoint inhibitor-induced colitis: clinical and transcriptomic correlates.

New evidencebiomarkertranslational
Clinical takeawayEndoscopic phenotype may help identify high-risk ICI colitis; no treatment strategy was tested, but oral second-generation corticosteroids achieved >80% remission in MES 0-1 disease, and re-challenge was followed by recurrence in about 37%, typically no more severe.
What it foundIn 250 patients from two UK centres, ICI colitis fell into mild inflammation (MES 0-1: non-microscopic 69.4%, microscopic colitis 10.5%) and moderate-to-severe colitis (MES 2-3, 20%). Bloody stool, anti-CTLA-4 therapy and anti-PD-(L)1 plus chemotherapy independently predicted moderate-to-severe disease (AUC 0.79).
ContextThe authors call CTCAE diarrhoea grading imprecise and propose this phenotype classification; transcriptomic profiling (18 patients) found a shared inflammatory programme, with VEGF signalling and matrix remodelling enriched in moderate-to-severe disease.
Refinessuggested applicable standard· American Gastroenterological Association (AGA), "AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review" (Dougan M, Wang Y, Rubio-Tapia A, Lim JK), Gastroenterology 2021;160(4):1384-1393

… The AGA cautions that no validated severity index for ICI colitis exists and that symptoms correlate poorly with endoscopic, radiologic, and treatment-response severity, and that rapid progression over days can occur, particularly with ipilimumab. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For suspected ICI colitis, exclude infectious causes of diarrhea (including C. difficile) before treating. In grade 2 or higher colitis/diarrhea, early stool inflammatory markers (lactoferrin, calprotectin) may help stratify patients for endoscopy, and endoscopic confirmation of the diagnosis and severity should be considered before starting high-dose systemic glucocorticoids; abdominal imaging is reserved for dominant pain, fever, or bleeding and should not be done routinely for diarrhea alone. The AGA cautions that no validated severity index for ICI colitis exists and that symptoms correlate poorly with endoscopic, radiologic, and treatment-response severity, and that rapid progression over days can occur, particularly with ipilimumab. ICI colitis typically responds to high-dose systemic glucocorticoids at 0.5-2 mg/kg prednisone-equivalent daily tapered over 4-6 weeks (the AGA explicitly notes these doses and schedules have not been rigorously examined). If there is no improvement after 2-3 days, add infliximab or vedolizumab while continuing glucocorticoids; both are reasonable options for glucocorticoid-refractory colitis. Budesonide is ineffective as prophylaxis and is not a standard treatment for ICI colitis, it is reserved for ICI-associated microscopic colitis. Retreatment with immunotherapy is possible under select conditions. For hepatitis, obtain baseline liver chemistries (total bilirubin, alkaline phosphatase, AST, ALT) and HBV serologies before ICI; grade by CTCAE and manage as follows: grade 1 (AST/ALT 1-3x ULN or bilirubin 1-1.5x ULN), monitor liver chemistries 1-2 times weekly; grade 2 (AST/ALT >3-5x ULN or bilirubin >1.5-3x ULN), hold ICI until resolution to grade 1, and if symptomatic give prednisone 0.5-1.0 mg/kg/d or equivalent; grade 3 (AST/ALT >5-20x ULN or bilirubin >3-10x ULN), discontinue ICI and start methylprednisolone 1-2 mg/kg/d or equivalent; grade 4 (AST/ALT >20x ULN or bilirubin >10x ULN or hepatic decompensation), permanently discontinue ICI and start methylprednisolone 2 mg/kg/d. For ICI hepatitis that does not adequately improve after 3-5 days of high-dose glucocorticoids, escalate to a second-line immunosuppressant, mycophenolate mofetil (with azathioprine as an accepted alternative), while continuing glucocorticoids; infliximab is not recommended for ICI hepatitis because of its potential for hepatotoxicity. Evaluate all ICI-related liver-chemistry elevations for alternate etiologies (consider liver biopsy), and obtain biliary imaging when alkaline phosphatase and/or bilirubin are elevated.

American Gastroenterological Association (AGA), "AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review" (Dougan M, Wang Y, Rubio-Tapia A, Lim JK), Gastroenterology 2021;160(4):1384-1393 · reviewed 2026-07-23 ↗
Ibraheim H … Powell N · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Endoscopy retrospective · n=1,217 · Nov 12, 2026 · J Clin Gastro · IF 2.9

Natural History and Predictors of Progression in Gastric Intestinal Metaplasia: An Australian Longitudinal Cohort Study.

New evidenceepidemiologybiomarker
Clinical takeawayContinue to follow the standard of care for surveillance in patients with extensive GIM or family history of gastric cancer
What it foundGIM patients had a 7.2% progression rate to dysplasia or cancer vs. 0.5% in non-GIM patients, with family history of GC (HR=4.9) and extensive GIM (HR=8.0) as independent predictors.
ContextThis literature reports that gastric intestinal metaplasia (GIM) is a premalignant lesion with a low progression rate to dysplasia or gastric cancer, highlighting its potential role in endoscopic surveillance.
Reinforcessuggested applicable standard· European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34)

Decision at stakefollow up patients with extensive endoscopic changes or advanced histological stage

… Follow up patients with extensive endoscopic changes (Kimura C3+ or EGGIM 5+) OR an advanced histological stage that reaches OLGA/OLGIM III/IV, severe atrophy or intestinal metaplasia and/or significant changes in both antrum and corpus rising to stage III/IV, not any intestinal metaplasia or any antrum-plus-corpus involvement on its own, with high quality endoscopy every 3 years, irrespective of country of origin (strong recommendation, moderate quality). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Perform individual gastric risk assessment and staging of precancerous conditions at first-time gastroscopy, irrespective of the patient's country of origin. Use high quality endoscopy with virtual chromoendoscopy (VCE), after proper training, for screening, diagnosis and staging of atrophy and intestinal metaplasia and after endoscopic therapy; VCE guides the biopsy site, with random biopsies taken only when there are no endoscopically suspected changes. Take biopsies from at least two topographic sites, 2 from the antrum/incisura and 2 from the corpus, VCE-guided, in two separate, clearly labeled vials; an additional incisura biopsy is optional, not required. Stage with validated endoscopic classifications of atrophy (e.g. Kimura-Takemoto) or intestinal metaplasia (e.g. EGGIM) to stratify gastric cancer risk (suggestion, weaker than the biopsy recommendation). Follow up patients with extensive endoscopic changes (Kimura C3+ or EGGIM 5+) OR an advanced histological stage that reaches OLGA/OLGIM III/IV, severe atrophy or intestinal metaplasia and/or significant changes in both antrum and corpus rising to stage III/IV, not any intestinal metaplasia or any antrum-plus-corpus involvement on its own, with high quality endoscopy every 3 years, irrespective of country of origin (strong recommendation, moderate quality). Propose NO surveillance for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history of gastric cancer, incomplete intestinal metaplasia, persistent H. pylori infection), the guideline states this group constitutes most individuals found in clinical practice. Eradicate H. pylori in all patients with precancerous conditions and after endoscopic or surgical therapy. Discontinue or do not start gastric cancer screening or surveillance in asymptomatic individuals over 80, and weigh comorbidities when planning treatment of superficial lesions. Advise smoking cessation; low-dose daily aspirin may be considered for gastric cancer prevention only in selected individuals already at high cardiovascular risk. For visible neoplasia, use ESD for differentiated lesions clinically staged as dysplastic (low or high grade) or intramucosal carcinoma (any size if not ulcerated, or ≤30 mm if ulcerated), with EMR an alternative for Paris 0-IIa lesions ≤10 mm with low likelihood of malignancy. At the population level, endoscopic screening is suggested every 2-3 years in high-risk regions (age-standardized rate >20 per 100,000 person-years), every 5 years in intermediate-risk regions (ASR 10-20) only if cost-effectiveness has been proven, and not at all in low-risk regions (ASR <10).

European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP), "Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Guideline update 2025", Endoscopy, 2025 (Recommendations 31 and 34) · reviewed 2026-07-23 ↗
Tjandra D … Boussioutas A · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Endoscopy prospective cohort · n=31 · Nov 13, 2026 · GIE · IF 8.0

Cryoballoon Ablation for Eradication of Sporadic and Familial Non-Ampullary Proximal Duodenal Adenomas (with video).

New evidencepolypectomyEMRESD
Clinical takeawayThe authors call cryoballoon ablation a possible alternative for selected proximal adenomas (1-5 cm, under 4 mm thick, under 50% of the circumference, fewer than 3 folds); the trial had no resection comparison and FAP numbers were small (5 patients).
What it foundComplete endoscopic and histologic eradication in 27/31 patients (87%) and 34/43 adenomas (79%), similar for sporadic (88%) and FAP (80%) disease; all adenomas <2 cm were eradicated, and size independently predicted eradication. Spigelman class fell in 3 of 5 FAP patients; no treatment-related serious adverse events occurred.
ContextThis study introduces a novel endoscopic technique for duodenal adenomas, which are typically managed with endoscopic resection due to risk of progression. The study included both sporadic and familial adenomatous polyposis (FAP) patients.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Canto MI … Trindade AJ · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy prospective cohort · n=41 · Nov 11, 2026 · J Gastro Hep · IF 3.5

Rapid Acquisition of Complex Procedural Skills Using Simulation-Based Mastery Learning: A Multicenter Study in Gastroenterology Fellows.

New evidenceendoscopy qualitycomputer-aided detectionsedationartificial intelligence
Clinical takeawayConsider simulation-based mastery learning (SBML) for novice gastroenterology fellows; the gain was on simulated upper endoscopy in a quasi-experimental comparison, and knowledge and self-efficacy were similar.
What it foundAll 26 (100%) first-year fellows achieved mastery in simulated upper endoscopy after 5-day SBML training, vs. 5/15 (33%) after 1-year apprenticeship (OR 22.8, 95% CI 3.8-136.0).
ContextChallenges traditional apprenticeship-based training, showing SBML achieves faster and more consistent mastery of simulated upper endoscopy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Soetikno R … Kaltenbach T · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
Endoscopy prospective cohort · n=3,416 · Nov 10, 2026 · BMC Gastro · IF 2.5

An explainable multimodal model integrating post-ESD mucosal defect images and clinical features to predict delayed bleeding after colorectal endoscopic submucosal dissection.

New evidenceartificial intelligencecomputer-aided detectionESD
Clinical takeawayNo clinical action yet: a predictive model requiring external calibration and safety evaluation before guiding postoperative care.
What it foundPrismDB, a multimodal model integrating post-ESD mucosal defect images and clinical features, predicted delayed bleeding after colorectal ESD with AUC 0.804 (95% CI 0.769-0.837), sensitivity 64.73%, specificity 85.40%, and negative predictive value 96.50%.
ContextRefines current practice by incorporating mucosal defect images into delayed bleeding prediction, which existing tools omit.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Zhao H … Chen J · BMC Gastroenterology · IF 2.5 · PubMed ↗Permalink
Endoscopy retrospective · n=453 · Nov 12, 2026 · GIE · IF 8.0

Pre-puncture EUS-based prediction of technical failure during EUS-guided hepaticogastrostomy: development and internal validation of a three-factor model.

New evidenceEUScomputer-aided detectionartificial intelligence
Clinical takeawayNo clinical action yet: this is a retrospective model requiring prospective multicenter validation before use in decision-making.
What it foundA three-factor model (bile duct diameter, needle-duct angle, hepatic parenchymal length) predicted first-attempt EUS-HGS failure with AUC 0.932, identifying high-risk patients with a 51.9% failure rate, intermediate-risk with 9.0%, and low-risk with 1.7%. The optimal cutoff probability was 0.130, yielding 86.8% sensitivity and 85.5% specificity.
ContextChallenges current practice by identifying pre-puncture anatomical predictors of EUS-HGS failure, which were previously assessed only post-puncture.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Ogura T … Liao SC · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy review · Nov 9, 2026 · J Clin Gastro · IF 2.9

WGO AI Guidelines: Manuscript 3 AI on the Horizon-Part I Review on AI in Upper GI and Biliopancreatic Endoscopy.

New evidenceartificial intelligencecomputer-aided detectioncholangiocarcinomaEUS
Clinical takeawayNo clinical action yet: AI in EUS and upper GI endoscopy remains investigational, requiring prospective multicenter validation and real-time clinical integration.
What it foundAI models applied to EUS images and videos show encouraging results in lesion detection, characterization, and risk stratification, in some cases matching or exceeding expert-level performance.
ContextThis review highlights the potential of AI to address operator-dependent variability and moderate accuracy in EUS and upper GI endoscopy, but current evidence is largely retrospective and single-center.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Saraiva MM … WGO AI Task Force Consortium · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
← Back to issue №20 Every section of this issue is one click away, at the top of this page. Follow Endoscopy by RSS